Randomized phase Ⅱ trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell Non-Hodgkin lymphoma: final analysis of the GAUSS study

查看全文 作　　者：Sehn LH; Goy A; Offner FC; 出　　处：《J Clin Oncol》索引2015年第33卷第30期,共0页